Current Understanding of Urachal Adenocarcinoma and Management Strategy

被引:40
作者
Claps, Melanie [1 ]
Stellato, Marco [1 ]
Zattarin, Emma [1 ]
Mennitto, Alessia [1 ]
Sepe, Pierangela [1 ]
Guadalupi, Valentina [1 ]
Mennitto, Roberta [1 ]
de Braud, Filippo G. M. [1 ]
Verzoni, Elena [1 ]
Procopio, Giuseppe [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol, Milan, Italy
关键词
Urachal carcinoma; Update in diagnosis; Molecular biology; Target therapy; Chemotherapy; Immunotherapy; MICROSATELLITE-INSTABILITY; PALLIATIVE CHEMOTHERAPY; EPITHELIAL NEOPLASMS; PARTIAL CYSTECTOMY; CARCINOMA; CANCER; BLADDER; FLUOROURACIL; PANITUMUMAB; DOXORUBICIN;
D O I
10.1007/s11912-020-0878-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians. Recent Findings UC is a rare and aggressive disease with consequent few data about diagnosis and treatment. Dates are mainly based on retrospective trial and case reports with limited prospective trial. Clinical presentation is not specific, often with urinary symptoms. Diagnosis is mainly based on CT scan and MRI, useful to evaluate local invasion and nodal status and to detect the presence of distant metastases. Therefore, biopsy is needed to obtain histological confirmation. Surgery is the gold standard for localized disease, while different chemotherapy schemes have been used in metastatic setting. Novel findings based on mutational analysis of the tumor include the use of biological treatment, such as cetuximab, and immunotherapy, such as atezolizumab, with satisfactory responses, suggesting that personalized treatment could be the most suitable option for UC.
引用
收藏
页数:8
相关论文
共 64 条
[1]  
Aggarwal Ajay, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2018-226207
[2]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[3]  
[Anonymous], PEDIAT UROLOGY
[4]  
[Anonymous], GEC ESTRO HDB BRACHY
[5]   Urachal carcinoma: Clinicopathologic features and long-term outcomes of an aggressive malignancy [J].
Ashley, Richard A. ;
Inman, Brant A. ;
Sebo, Thomas J. ;
Leibovich, Bradley C. ;
Blute, Michael L. ;
Kwon, Eugene D. ;
Zincke, Horst .
CANCER, 2006, 107 (04) :712-720
[6]   Genetics and biological markers in urachal cancer [J].
Behrendt, Mark A. ;
van Rhijn, Bas W. G. .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2016, 5 (05) :655-661
[7]   Clinical comparison of patients with benign urachal masses versus urachal carcinomas [J].
Bi, Xing ;
Wu, Zhiming ;
Han, Hui ;
Zhou, Fangjian .
CHINESE JOURNAL OF CANCER, 2017, 36
[8]   The Clinical Epidemiology of Urachal Carcinoma: Results of a Large, Population Based Study [J].
Bruins, H. Max ;
Visser, Otto ;
Ploeg, Martine ;
Hulsbergen-van de Kaa, Christina A. ;
Kiemeney, Lambertus A. L. M. ;
Witjes, J. Alfred .
JOURNAL OF UROLOGY, 2012, 188 (04) :1102-1107
[9]   Investigating urachal carcinoma for more than 15 years [J].
Chen, Duqun ;
Li, Yifan ;
Yu, Zuhu ;
Su, Zhengming ;
Ni, Liangchao ;
Gui, Yaoting ;
Yang, Shangqi ;
Shi, Bentao ;
Lai, Yongqing .
ONCOLOGY LETTERS, 2014, 8 (05) :2279-2283
[10]   Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition [J].
Collazo-Lorduy, Ana ;
Castillo-Martin, Mireia ;
Wang, Li ;
Patel, Vaibhav ;
Iyer, Gopa ;
Jordan, Emmet ;
Al-Ahmadie, Hikmat ;
Leonard, Issa ;
Oh, William K. ;
Zhu, Jun ;
McBride, Russell B. ;
Cordon-Cardo, Carlos ;
Solit, David B. ;
Sfakianos, John P. ;
Galsky, Matthew D. .
EUROPEAN UROLOGY, 2016, 70 (05) :771-775